Skip to main content

Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements

Bristol Myers Squibb (NYSE:BMY) today announced that it has entered into accelerated share repurchase (ASR) transactions under agreements with Morgan Stanley & Co. LLC, Barclays Bank PLC, Citibank, N.A. and JPMorgan Chase Bank, N.A., (collectively, the “ASR Agreements”) to repurchase, in aggregate, $5 billion of Bristol Myers Squibb common stock.

Under the ASR Agreements, the ASR transactions will be completed under a previously announced $15 billion board-authorized multi-year share repurchase program, under which the company will have approximately $10.2 billion of remaining share repurchase authorization after giving effect to the ASR transactions. Bristol Myers Squibb expects to fund the repurchases with cash on-hand. Approximately 85 percent of the shares to be repurchased under the ASR transactions will be received by Bristol-Myers Squibb on February 9, 2022. The total number of shares ultimately repurchased under the ASR transactions will be determined upon final settlement and will be based on a discount to the volume-weighted average price of Bristol-Myers Squibb’s common stock during the terms of the ASR transactions. Bristol-Myers Squibb anticipates that these ASR transactions will be settled during the second and third quarters of 2022.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the settlement of the ASR Agreements. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2020, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.



Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.